SCHEMBL5583500

SCHEMBL5583500

CCc1cc2c(c(-c3ccccc3Cl)c1)O[CH]C2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
CSNK2A3 Q8NEV1 1/20 0.34
POLB P06746 1/20 0.34
HTR1A P08908 6/20 0.33
HTR7 P34969 6/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PLA2G7 Q13093 1/20 0.32
DPP4 P27487 1/20 0.32
USP7 Q93009 1/20 0.31
HPGD P15428 1/20 0.31
HTR2C P28335 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27723655 0.81 PLA2G7 (0.37) POLBHTR1AHTR7NPC1ALDH1A1
SCHEMBL27723786 0.81 CSNK2A2 (0.38) CSNK2A2CSNK2BCSNK2A1CSNK2A3NPC1
SCHEMBL5586510 0.78 AQP1 (0.38) POLBHTR1AHTR7NPC1ALDH1A1
SCHEMBL4596349 0.76 GRM2 (0.38) HTR1AHTR7ALDH1A1
SCHEMBL27703057 0.75 TACR1 (0.37) NPC1ALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL4596345 0.75 AQP1 (0.35) CSNK2A2CSNK2BCSNK2A1CSNK2A3HTR1A
SCHEMBL4232272 0.73 AQP1 (0.53) CSNK2A2CSNK2BCSNK2A1CSNK2A3HTR1A
SCHEMBL5595803 0.70 CNR2 (0.33) NPC1ALDH1A1LMNAMAPTRAB9A
SCHEMBL5583498 0.68 AQP1 (0.38) NPC1ALDH1A1LMNAMAPTRAB9A
SCHEMBL4960925 0.67 AQP1 (0.43) POLBNPC1ALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101448492-A Methods of treating cognitive and other disorders WYETH CORP (US) 2009-06-03 CN claimed
CN-101389325-A Treatment of drug abuse WYETH CORP (US) 2009-03-18 CN claimed
CN-101203217-A Methods for modulating bladder function WYETH CORP (US) 2008-06-18 CN claimed
CN-101203216-A Dihydrobenzofuran derivatives and uses thereof WYETH CORP (US) 2008-06-18 CN claimed
CN-101198323-A Therapeutic combinations for the treatment or prevention of psychotic disorders WYETH CORP (US) 2008-06-11 CN claimed
CN-101198322-A Novel therapeutic combinations for the treatment or prevention of depression WYETH CORP (US) 2008-06-11 CN claimed
CN-101189004-A Treatment of pain WYETH CORP (US) 2008-05-28 CN claimed
JP-2007509174-A 2007-04-12 JP claimed
EP-1675840-A1 DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS Wyeth a Corporation of the State of Delaware (US) 2006-07-05 EP claimed
WO-2005044812-A1 DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS WYETH A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 WO claimed
CN-101448492-A Methods of treating cognitive and other disorders WYETH CORP (US) 2009-06-03 CN disclosed
CN-101389325-A Treatment of drug abuse WYETH CORP (US) 2009-03-18 CN disclosed
CN-101203217-A Methods for modulating bladder function WYETH CORP (US) 2008-06-18 CN disclosed
CN-101203216-A Dihydrobenzofuran derivatives and uses thereof WYETH CORP (US) 2008-06-18 CN disclosed
CN-101198323-A Therapeutic combinations for the treatment or prevention of psychotic disorders WYETH CORP (US) 2008-06-11 CN disclosed
CN-101198322-A Novel therapeutic combinations for the treatment or prevention of depression WYETH CORP (US) 2008-06-11 CN disclosed
CN-101189004-A Treatment of pain WYETH CORP (US) 2008-05-28 CN disclosed